Hironaga Satake

Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer

Kohei Shitara, Eric Van Cutsem, Yung‐Jue Bang et al. · JAMA Oncology · 2020 · 1.1K citations · Full text

Sotorasib in <i>KRAS</i> p.G12C–Mutated Advanced Pancreatic Cancer

John H. Strickler, Hironaga Satake, Thomas J. George et al. · New England Journal of Medicine · 2022 · 425 citations · Full text

Propensity Score Analysis of Regorafenib Versus Trifluridine/Tipiracil in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy (REGOTAS): A Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study

Toshikazu Moriwaki, Shota Fukuoka, Hiroya Taniguchi et al. · The Oncologist · 2017 · 104 citations · Full text

Long-term outcome of transoral organ-preserving pharyngeal endoscopic resection for superficial pharyngeal cancer

Manabu Muto, Hironaga Satake, Tomonori Yano et al. · Gastrointestinal Endoscopy · 2011 · 98 citations

Surgical Oncology, Minimally Invasive Procedure, Long-term Outcome +5

Re-evaluation of HER2 status in patients with HER2-positive advanced or recurrent gastric cancer refractory to trastuzumab (KSCC1604)

Hiroshi Saeki, Eiji Oki, Tomomi Kashiwada et al. · European Journal of Cancer · 2018 · 97 citations

Her2 Status, Surgical Oncology, Oncology +6